drugset / Trial / NCT06669650
Personalized Post-Operative Pain Management
RandomizedParallel-groupOpen-labelPrevention
Summary
The main questions this study aims to answer are: Does perioperative PGx personalized opiate therapy reduce persistent post-operative opioid use dependency, improve pain management and reduce opiate related adverse events in opioid naïve patients after surgery? Participants will: Take hydromorphone if the PGx results determine they have a SNP indicating high or low metabolic activity in the CYP2D6 enzyme. Complete a 7-day pain diary post-discharge. Complete a follow-up phone call once per month for 90 days.
Timeline
- Start
- 2024-09-25
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 2 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 4 mg | Oral |
| Comparator | Oxycodone | Other / unclassified | 5 mg | — |
| Comparator | Oxycodone | Other / unclassified | 10 mg | — |